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Introduction: Patient suitability to anti–programmed death
ligand 1 (PD-L1) immune checkpoint inhibition is key to the
treatment of NSCLC. We present, applied to PD-L1 testing: a
comprehensive cross-validation of two immunohistochem-
istry (IHC) clones; our descriptive experience in diagnostic
reﬂex testing; the concordance of IHC to in situ RNA
(RNA-ISH); and application of digital pathology.
Methods: Eight hundred thirteen NSCLC tumor samples
collected from 564 diagnostic samples were analyzed
prospectively, and 249 diagnostic samples analyzed retro-
spectively in tissue microarray format. Validated methods
for IHC and RNA-ISH were tested in tissue microarrays and
full sections and the QuPath system were used for digital
pathology analysis.
Results: Antibody concordance of clones SP263 and 22C3
validation was 97% to 98% in squamous cell carcinoma and
adenocarcinomas, respectively. Clinical NSCLC cases were
reported as PD-L1–negative (48%), 1% to 49% (23%), and
more than 50% (29%), with differences associated to tissue-
type and EGFR status. Comparison of IHC and RNA-ISH was
highly concordant in both subgroups. Comparison of digital
assessment versus manual assessment was highly concor-
dant. Discrepancies were mostly around the 1% clinical
threshold. Challenging IHC interpretation included 1)
calculating the total tumor cell denominator and the nature
of PD-L1 expressing cell aggregates in cytology samples; 2)
peritumoral expression of positive immune cells; 3) calcu-
lation of positive tumor percentages around clinical thresh-
olds; and 4) relevance of the 100 malignant cell rule.Conclusions: Sample type and EGFR status dictate differ-
ences in the expected percentage of PD-L1 expression.
Analysis of PD-L1 is challenging, and interpretative guide-
lines are discussed. PD-L1 evaluations byRNA-ISH anddigital
pathology appear reliable, particularly in adenocarcinomas.
 2018 Published by Elsevier Inc. on behalf of International
Association for the Study of Lung Cancer.
Keywords: Validation; Programmed death ligand 1; Clinical
workﬂow; RNAscope; Image analysisIntroduction
Immune checkpoint blockade therapy is a new
paradigm in cancer treatment with durable tumor
regression and prolonged stabilization of disease in
patients with advanced cancers, including NSCLC.1,2 TheJournal of Thoracic Oncology Vol. - No. -: ---
2 Humphries et al Journal of Thoracic Oncology Vol. - No. -binding of programmed death-1 receptor (PD-1) to its
ligand programmed death ligand 1 (PD-L1) plays a
pivotal role in the ability of tumor cells to evade the
host’s immune system.3 PD-L1 may be highly expressed
on the surface of tumor cells. Binding of PD-1 with PD-L1
inhibits T cell activation, allowing immunosuppression
and neoplastic growth.4 Blockade of this interaction has
yielded long-lasting clinical beneﬁts in many patients.
Despite the clinical efﬁcacy observed, many cancer pa-
tients do not respond to PD-1/PD-L1 checkpoint inhibi-
tion. Along with PD-L1 expression, other markers such
as microsatellite instability and tumor mutation burden,
as well as understanding the role of other markers and
the function of tumor inﬁltrating immune and stromal
cells in the tumor microenvironment may be important
in predicting clinical beneﬁt of immune checkpoint
inhibition and determining optimal combination
therapies.5-10
In 2016, pembrolizumab was given European Medi-
cines Agency approval for ﬁrst-line treatment of meta-
static or locally advanced squamous and non-squamous
NSCLC.11 Patients with an identiﬁed PD-L1 expression
may be treated with pembrolizumab based on PD-L1
expression equal to or greater than 1% in second-line
treatment or where PD-L1 expression is equal to or
greater than 50% in ﬁrst-line treatment.11,12
There are many PD-L1 antibodies and scoring sys-
tems currently in use.13 Four PD-L1 assays with four
distinct antibodies and two separate automated staining
patterns are registered with the U.S. Food and Drug
Administration. This raised many questions about inter-
and intralaboratory variations in assessment of PD-L1
expression. The current literature however, appears to
have reached a consensus.14-16 Dako 28-8, Dako 22C3,
and Ventana SP263 are closely similar, showing strong
and comparable expression on the tumor cells of the
NSCLC, but delineating fewer immune cancer-associated
cells, and thus have higher sensitivity to the performance
of Ventana SP142.17
Despite this apparent similarity, the validation and
application of PD-L1 immunohistochemistry (IHC) for
diagnostics is fraught with challenges. Subtle discor-
dance between antibodies, separation of tumor cell
versus inﬂammatory cell PD-L1 chromogenic signals,
apparent focal signal mislocalization from the membrane
to the cytoplasm, scoring of percentages of expression
(particularly around the thresholds of clinical relevance
less than 1% and 50%) or speciﬁc dilemmas associated
to small biopsy and cytology samples.
Hereby we present a comprehensive assessment of
the PD-L1 IHC diagnostic test in NSCLC at different
levels: (1) a comparative cross-validation of the two
more widely used antibodies, namely the Dako 22C3 and
Ventana SP263 clones; (2) a description of clinical PD-L1reﬂex testing in the ﬁrst 564 cases in an accredited
laboratory; (3) the concordance of PD-L1 overexpression
by IHC versus PD-L1 upregulation by in situ RNA (RNA-
ISH); and (4) the potential role of digital pathology in the
automated scoring using open source available software
(QuPath).Materials and Methods
Comparative Validation
Clinical Samples. The total number of cases submitted
for PD-L1 assessment as a reﬂex test was 583 over a 12
month period, across four National Health Service trusts
in Northern Ireland. Five hundred sixty-four patient
samples had adequate or complete data for retrospective
analysis. The sample types included formalin-ﬁxed
parafﬁn-embedded cell blocks (n ¼ 88), bronchoscopic
and core biopsy specimens (n ¼ 429), and surgical re-
sections (n ¼ 66). The reﬂex testing (in adenocarcinoma)
included PD-L1 protein overexpression, ALK receptor
tyrosine kinase (ALK) IHC, and EGFR mutational status.
Research Samples. A total of 249 cancer samples, rep-
resented by 120 tissue cores of lung adenocarcinoma
and 114 cores of lung squamous cell carcinomas in a
tissue microarray (TMA) format as well as 15 whole-face
sections from patients who underwent surgery with
curative intent from 2005 to 2015 at The Belfast Health
and Social Care Trust were used.
Ethical approval was obtained and tissue was ac-
quired through the Northern Ireland Biobank (reference:
12-00168). For adenocarcinoma, predominant histologic
pattern (solid, lepidic, acinar, papillary, and micro-
papillary) was determined according to the 2015 WHO
classiﬁcation.18 For squamous cell carcinoma grading,
we used well, moderate, and poorly differentiated cate-
gories. The TMA blocks were prepared using 1.0-mm
tissue cores as described previously and using national
guidelines.19,20 EGFR mutation data obtained using
COBAS or Sanger sequencing was available in 250 cases
of adenocarcinoma. ALK fusion protein expression data
was obtained using ALK IHC, only in adenocarcinoma,
with the D5F3 clone on a Ventana BenchMark platform
and was positive in 7 of 407 adenocarcinoma cases. This
was complemented by a cohort of 15 whole-face sections
(8 adenocarcinomas and 7 squamous cell carcinomas).
IHC Staining. Three-micrometer-thick sequential histo-
logic tumor sections were obtained from representative
formalin-ﬁxed parafﬁn-embedded tumor blocks (whole-
face or TMA) and used for IHC analysis. IHC was per-
formed using an automated staining system (Ventana
BenchMark) with antibodies against PD-L1 (SP263 clone,
Ventana, CC1 pre-treatment for 64 minutes, Ventana
--- 2018 Critical Appraisal of PD-L1 Reﬂex Testing 3Optiview detection protocol) or using a Dako automated
platform with antibody to the 22C3 clone of PD-L1. Both
systems used a diaminobenzidine reaction to detect
antibody labeling and hematoxylin counterstaining.
Strategy of Comparative Validation. Serial sections
from lung adenocarcinoma or lung squamous carci-
nomas (whole-face or TMAs) were stained for PD-L1
(SP263 clone) in The Northern Ireland Molecular Pa-
thology Laboratory (Belfast) or for PD-L1 (22C3 clone)
in Southampton (University Hospital of Southampton,
NHS Trust). Assessment of PD-L1 was performed by
two individuals (M.S.T. and S.M.) who have received
training and are certiﬁed competent for PD-L1 scoring
in accordance with recognized parameters. In each
whole-face section or TMA core the criteria in box 1
(Supplemental Table 1) were used in the scoring as-
sessments.21 Internal positive control tissues were to
represent the different expression patterns of PD-L1 as
well as tonsil tissue with strong expression observed
in crypts and weaker expression in follicles.PD-L1 Testing in Routine Practice
From April 2017 to March 2018, 564 patient samples
were tested and reports issued. All samples were clini-
cally assessed by teams of two individuals who received
training and are certiﬁed competent for PD-L1 scoring.
Sections from a small internal TMA consisting of four
cores (representing PD-L1 expression levels of more
than 50%, 1% to 49%, and less than1%, as well as
tonsil) were used in each test run to assess speciﬁcity
and sensitivity and intra-run reproducibility.RNA-ISH Assay
Method. Automated RNAscope for PD-L1 was per-
formed on sections from the adenocarcinoma and
squamous cell carcinoma TMAs on a Leica Bond RX
platform. Brieﬂy, sections were cut at 4 mm, air dried
overnight, baked at 60C for 1 hour, dewaxed, and air-
dried before pretreatments. For all tissue sections, a
standard pretreatment protocol was used. Three RNA-
Scope probes from Advanced Cell Diagnostics (ACD;
Hayward, California) were used in this study: positive-
control probe Hs-PPIB (313908 Accession #
NM_000942.4-4 – 139 - 989); and probe to the immune
pathway–associated biomarker PD-L1 – Hs-CD274
(600868 Accession # NM_014143.3 – sequence region
124 - 1122) were also used to stain the lung TMAs. Also
a negative-control probe DapB (312038 Accession #
NM_EF191515) was tested in a subset of adenocarci-
noma and squamous cell carcinoma TMA cases with noexpression observed on any cores. Detection of speciﬁc
probe binding sites done was with the RNAScope 2.5 HD
Reagent kit-brown from ACD (Cat. No. 322300).
Materials and Scoring System. Thirty lung adenocar-
cinomas and 30 lung squamous cell carcinomas in
TMA format were assessed for overall expression of
PD-L1 by IHC and by RNAscope. These cases in TMA
format were selected according to immediate avail-
ability, thus, they represent a cross-section of all
samples submitted to a routine diagnostic lab. For IHC,
cases were classiﬁed as less than 1%, 1% to 49%, or
more than 50% PD-L1 expression on tumor cells,
taking into account all available tumor in all cores for
the individual cases. For PD-L1, mRNA expression by
RNAscope cases were classiﬁed as less than 1%
expression on tumor cells (no staining or just one dot
per call in a few tumor cells), 1% to 49% of tumor
cells have two or more dots per cell, or more than
50% of tumor cells have two or more dots per cell
with many foci having abundant dots-per-cell. All
RNAscope assessments were performed by two in-
dividuals (S.M. and V.B.) who are experienced users of
the RNAscope assay.22,23Image Analysis of PD-L1 Expression
Digital image analysis of the IHC stained TMA
slides or clinical cases was performed using an in-
house image analysis program called QuPath.24,25 All
slides were scanned on an Aperio AT2 digital scanner
at 40 and imported into the program. Following an
established method, tissue detection was performed by
identifying the tissue for cellular analysis.24 Samples
that contained less than 100 tumor cells were
excluded from analysis. Rigorous quality control (QC)
steps were taken to remove necrosis or keratin, tissue
folds, and entrapped normal structures; this was
conﬁrmed by a second reviewer with frequent
consultation. Carbon pigment was also edited out to
avoid these deposits being interpreted as positive cells.
Furthermore, PD-L1 expression by macrophages is
well recognized and these were manually edited out
where possible to minimize the risk of false-positive
detections. For manual evaluation, a positive cell was
deﬁned as one which showed a pattern of membrane
staining of any intensity. QuPath’s ability to classify
cell types within each tissue core was applied to
distinguish tumor and stroma compartments.
Quantitation was conducted as previously
described.24 Cores included in QuPath analysis were also
manually assessed in a blinded fashion as described
above and a percentage of tumor-positive cells recorded.
Figure 1. Summary of the validation on tissue microarrays of the programmed death ligand 1 (PD-L1) SP263 clone on Ventana
BenchMark against the Dako PD-L1 22C3 clone on the Dako Autostainer Link 48 in (A) lung adenocarcinomas and (B) squamous
cell carcinomas. A very high level of concordance was observed. For adenocarcinomas, there were 111 of 113 tissue
microarray (TMA) cores (98%); and for squamous cell carcinomas, there were 100 of 103 TMA cores (97%). (C) For (i) 22C3 and
(ii) SP263 there is no PD-L1 expression in lung adenocarcinoma, whereas (iii) 22C3 and (iv) SP263 show comparable expression
of more than 50% on tumor epithelium in a squamous cell carcinoma. And in (v) 22C3, two or three tumor epithelial cells are
expressing PD-L1, but this expression was not observed in a serial core with the SP263 clone (vi).
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Comparative Validation of PD-L1
The concordance between the assessment of PD-L1
expression (SP263 clone) on a Ventana BenchMark
platform and PD-L1 expression (22C3 clone) on a Dako
Autostainer platform is shown in Figure 1. Of TMA cores
that were available for assessment, 111 of 113 TMA
cores from adenocarcinomas were fully concordant with
an overall concordance rate of 98% (Fig. 1A). One hun-
dred of 103 TMA cores from squamous cell carcinomas
were fully concordant with an overall concordance rate
of 97% (Fig. 1B). In 58 adenocarcinomas and 58 squa-
mous cell carcinomas, no expression was seen with
either clone (Fig. 1C, parts i and ii). In 27 adenocarci-
noma and 33 squamous cell carcinomas, concordance
was observed at over 50% expression (Fig. 1C, parts iii
and iv). In two cases of adenocarcinoma, the 22C3
clone showed expression on a few tumor epithelial cells,
which was assessed in the cores as 1% and 2%,
respectively (Fig. 1C, part v). The same cell populations
did not show expression with the SP263 clone (Fig. 1C
part vi). Similarly, two squamous cell carcinoma TMA
cores showed very low level expression with the 22C3
clone which were not observed with the SP263 clone. In
a single squamous cell carcinoma TMA core, the 22C3
clone showed more than 50% PD-L1 expression (65%);
however, only 1% to 49% expression (35%) PD-L1
expression was observed with the SP263 clone.For both antibody clones, overall scores for PD-L1
expression were fully concordant for 15 of 15 whole-
face resections of either adenocarcinoma or squamous
cell carcinoma of the lung. Five cases were assessed as
less than 1%, six cases as 1% to 49%, and four cases as
more than 50%.PD-L1 Testing in Routine Practice
Five hundred sixty-four of 583 samples were
available for analysis. Nineteen cases were found to be
inadequate for assessment (less than 100 tumor cells
in the sample) (Fig. 2A, inset). Eleven percent of the
adenocarcinomas were inadequate for PD-L1 testing,
with 3% determined inadequate for squamous cell
carcinoma histology (Figs. 2B and C insets,
respectively).
Of the 564 cases tested, 48% were PD-L1–negative
(less than 1% positive). With categories 1% to 49% and
more than 50%, PD-L1 positivity was reported as 23%
and 29%, respectively (Fig. 2A). There was little differ-
ence in PD-L1 categorization of cases within the twomain
histologic subtypes, adenocarcinoma and squamous cell
carcinoma (Figs. 2B and C). Representative hematoxylin
and eosin staining as well as images of PD-L1 categories
are shown in Figures 2D and E for adenocarcinomas and
squamous cell carcinomas, respectively.
Five hundred sixty-four cases included 74% biopsies,
15% cytology cell blocks, and 11% surgical resections
Figure 2. Comparable categorical distribution of programmed death ligand 1 (PD-L1) expression. (A) Within all 564 clinical
cases. (B) In adenocarcinomas. (C) In squamous cell carcinomas. Inadequate cases were deﬁned as those which had insuf-
ﬁcient tumor content (<100 malignant cells) available for analysis. (D, E) Left-to-right display representative images of (i)
hematoxylin and eosin staining (H&E), (ii) negative PD-L1 expression, (iii) 1% to 49% PD-L1 expression, and (iv) more than 50%
positive PD-L1 expression for adenocarcinoma and squamous cells carcinoma, respectively.
--- 2018 Critical Appraisal of PD-L1 Reﬂex Testing 5(Fig. 3A). The positivity of PD-L1 expression differed
across sample types. Within the more than 50% posi-
tivity clinical category there was relative consistency in
percentages of expressing cases (29% biopsy cases, 32%
cytology cases, and 25% surgical resections). In the 1%
to 49% clinical category, the percentage expressingFigure 3. Range of sample types tested, including tumor conte
(A) The range of samples types received for testing, resection,
availability did not signiﬁcantly affect the PD-L1 category det
value is determined by the chi-square test. (D) PD-L1 expressioPD-L1 is diminished in biopsies (22%) and cytologies
(20%) when compared with resections (33%), as shown
in Figure 3C.
Of the cases with PD-L1 categories determined,
EGFR mutational status was also investigated. Eighty-
six percent of the cases were found to be wild-typent available for programmed death ligand 1 (PD-L1) testing.
biopsy and cell block (CB). (B) Conﬁrms that tumor content
ermined. (C) PD-L1 expression according to sample type. p
n within the cases of differing EGFR status.
6 Humphries et al Journal of Thoracic Oncology Vol. - No. -for EGFR. Eight percent of cases were determined to
have point mutations, with 6% EGFR deletions. The
PD-L1 expression within the EGFR wild-type, mutation
or deletion was also evaluated (Fig. 3D).
The PD-L1 expression category was not inﬂuenced
by the availability of tumor content if more than 100
cells were available. Figure 3B shows the range of
tumor cells available for analysis and the clinical PD-
L1 category reported. There was no signiﬁcant differ-
ence across the PD-L1 clinical categories relative to
tumor content available for testing.Challenges in Routine PD-L1 Assessment
There are several challenges to routine PD-L1
assessment:
1. Percentage of positive cells in cytology samples —
the need for a “background stain.” PD-L1 expression
is reported as a percentage of existing malignant
cells that are expressing the antibody. Although the
denominator of this equation (total number of ma-
lignant cells) is clear in histology samples, in
cytology specimens this may not be so obvious, as
shown by a malignant lung epithelial IHC stain
thyroid transcription factor 1 (Fig. 4A).
2. Nests of positive cells on cytology — macrophages
or malignant cells. Figure 4B shows a case in whichFigure 4. Challenges with programmed death ligand 1 (PD-L1)
which are conﬁrmed by TTF1 expression a highly speciﬁc marker
more than 50% PD-L1 expression in tumor cells. (B) PD-L1 exp
notyped with macrophage and epithelial markers, were identiﬁe
(C) Resection of adenocarcinoma in which there is strong expr
Resection sample from squamous cell carcinoma shows distinc
more than 50% expression in various ﬁelds across the tumor bed
eosin.the nature of the positive PD-L1 cells had to be
elucidated by a comparison of HE, CD68, AE1/3,
and PD-L1 in consecutive sections of a cytology cell
block.
3. Tumor versus inﬂammation — the “hugging effect.”
Similarly, sometimes the presence of PD-L1 strongly
positive inﬂammatory cells around nests of malig-
nant epithelial cells is prominent (Fig. 4C). Here, the
rule is not to call something epithelial-positive un-
less there is unequivocal evidence that the staining
is also present in the malignant cells.
4. Calculation of percentages around the “clinical
thresholds.” Unlike the 2þ category when scoring of
Her2 in breast or gastric cancer, PD-L1 does not
have any “threshold/buffer” score on which we can
refer to other methods and, as such, there is a de-
gree of uncertainty when a sample has “a few
positive cells” (threshold of less than 1% to 2.7%,
an occurrence happening in 9 of 564 of the cases in
our reported experience), or “approximately half of
the malignant cells are positive” (threshold 40% to
60%).
5. One hundred malignant cell minimum — when is this
applicable? This rule aims to achieve a “minimum
representation” of the sample, particularly in view of
the notorious heterogeneity of PD-L1 expression
identiﬁed in some resection specimens (Fig. 4D). Inassessments. (A) PD-L1 expressing tumor cells in a cell block
for primary lung adenocarcinomas. The case was reported as
ression in foci of cells in a lung cell block which, when phe-
d as macrophages. The case was reported as PD-L1–negative.
ession of PD-L1 on lymphocytes which “hug” the tumor. (D)
t heterogeneity of PD-L1 expression ranging from absent to
. TTF-1, thyroid transcription factor 1; HE, hematoxylin and
--- 2018 Critical Appraisal of PD-L1 Reﬂex Testing 7cases of less than a 100-cell minimum in which the
cytology or biopsy sample is the only one available,
the percentage of positive malignant cells should be
reported with the diagnostic label of “unsatisfactory.”
These are summarized in Supplementary Table 1.Potential Use of Image Analysis and RNA-ISH for
PD-L1 Expression
The concordance of PD-L1 expression by IHC
(SP263 clone) and RNA-ISH in TMAs is shown in
Supplementary Figure 1. Excellent concordance was
seen between ICH and RNA-ISH. One case which by IHC
showed more than 50% expression did not show any
mRNA expression by RNA-ISH.
The concordance of manual PD-L1 assessment (the
current gold standard) with that of digital pathology
(QuPath) is shown in Supplementary Figure 2. In addi-
tion to the cases from routine diagnostics, we assessed
62 cases across all three clinical categories in our
squamous cell carcinoma and adenocarcinoma TMAs.
Supplementary Figure 2D and E show concordant and
discordant cases between manual and digital assessment
in a case which had high PD-L1 expression and Low PD-
L1 expression, respectively.Discussion
Despite the equivalence between PD-L1 antibodies,
the reported expression rates in lung adenocarcinoma
vary greatly.26-29 This may be a reﬂection of (1) the
sample cohorts analyzed; (2) the proportion of
different clinical sample-types in the studies; and (3)
the intrinsic difﬁculty of this test, particularly in the
areas of “diagnostic threshold.” Our clinical validation
conﬁrms the equivalence of the 22C3 and SP263 PD-L1
antibody clones, perhaps highlighting that when other
variables are corrected for (same interpretative team,
same rules of interpretation, and same samples) the
reported antibody equivalence should be obvious. In
our opinion, this calls for the development of “refer-
ence materials” for multicenter validation of tests such
as PD-L1 IHC.
The clinical experience on our ﬁrst 564 cases in-
dicates that, if the validation is correct, the sample type
may inﬂuence the result. However, the histologic
subtype does not have any relevance in the validation or
in the ﬁnal numbers. The PD-L1 expression pattern seen
in resections does not mirror exactly that seen in the
cytology and biopsy samples. This may be explained by
the heterogeneity of PD-L1 expression combined with an
increased tissue area for assessment which leads to an
increased reporting of 1% to 49% cases from resection
specimens, closer to the percentages in clinical trials. ThePD-L1 negative rate of 48% we report here is indifferent
to that reported in clinical trials (e.g., KEYNOTE-010 and
KEYNOTE-024). This can be explained by the fact that in
trials there is an attempt to retrieve a new sample, thus
increasing the availability of tissue not tested for other
purposes. Furthermore, there is a lack of acceptance of
ﬁne needle aspirates for testing in clinical trials.11 Our
real-world samples are different, with a predominance of
small volumes already tested for other biomarkers,
which possibly brings down the numbers of cases in the
1% to 49% category.
Our routine experience highlights potential areas of
diagnostic difﬁculty. We suggest the following possible
solutions, which can be consolidated into 3 points: (1)
Use other IHC markers when needed for interpretative
support. As a result, our policy for cytology samples is to
request, when possible, a “malignant lung epithelial IHC
stain” (TTF-1 or similar) to establish the true cellular
background and carry out the most accurate calculation.
Occasionally, upon encountering cases with a “hugging
effect”, the use of epithelial/inﬂammatory IHC antibodies
can be justiﬁed, and also evokes the potential use of
“double staining.” (2) Consult on the sample with a
trained colleague in quantitation when close to clinical
thresholds. And (3), make judicious use of the 100-cell
threshold rule in the patients’ clinical context. In cases
in which the cytology or biopsy sample is the only one
available, we report the percentage of positive malignant
cells if we detect a degree of expression to avoid the
label of “unsatisfactory,” as this may be of clinical rele-
vance. This is particularly important in cases where no
other specimen is available and/or further sampling may
not be possible.
In difﬁcult cases where positive immune cells sur-
round tumor nests, a so-called “hugging effect” is
evident; there may be a requirement for the application
of other IHC staining to conﬁrm epithelial cell positivity.
The advantage of this is primarily a conﬁdent reporting
of PD-L1 expression for the patient, with the main
disadvantages being the time and cost of IHC double
staining and/or multiplexing in routine diagnostics. In
cases where there is a difﬁculty in deciding if the PD-L1
signal originates in the malignant epithelial cells or in the
surrounding immune cells, we suggest the sample is
regarded as positive only if there is “unequivocal evi-
dence” of epithelial expression.
The concordance between PD-L1 IHC and RNA-ISH is
very good. It would be interesting to see if the small
percentage of discrepancy actually confers higher pre-
dictive value to the RNA-based analysis in treated
sample collections. RNA-ISH can be a quantitative
methodology and, as such, may represent a way forward
to bring consistency and concordance to this test; thus
making it a realistic diagnostic option.
8 Humphries et al Journal of Thoracic Oncology Vol. - No. -The subjective assessment of PD-L1 positivity may
provide an arena in which use of image analysis as a
companion diagnostic aid could be beneﬁcial. The accu-
racy and reproducibility of digital pathology may be
considered overall or in difﬁcult cases. In our hands,
digital pathology is demonstrably accurate in the anal-
ysis of PD-L1. The gold standard of assessment, namely
the human diagnostician, is able to qualify the discrep-
ancy upon review of the tumor classiﬁer applied by
digital pathology. The application of robust tumor clas-
siﬁers and deep learning in digital pathology may solve
the disparity between pathologist and machine or, when
applied to clinical trial material, show the superiority of
the in silico approach to scoring, as other studies are
beginning to suggest.30 In any case, the application of
digital pathology in clear-cut cases, thus requiring little
pathologist input, would enable pathologist to spend
more time analyzing cases within the difﬁcult diagnostic
thresholds.
One of the main characteristics of PD-L1 IHC scoring
is the common denominator, that is, the total number of
malignant cells. This can be calculable with relative ease
in histology samples, but it is signiﬁcantly more chal-
lenging in cytology samples with discohesive malignant
cells in benign, reactive cellular backgrounds. In this
context, the cross-reference to cancer cell–speciﬁc IHC
(such as TTF-1) is very important and unfortunately not
always available when the test is performed in referral
laboratories.
In summary, hereby we present a successful cross-
validation of PD-L1 as a diagnostic test, we discuss the
areas of interpretative difﬁculty associated to biopsies and
cytology, and we explore the pathway to make the test
more objective and quantiﬁable by incorporating RNA-
ISH and digital pathology scoring interpretation. This
may represent a validation footprint for other future ex-
amples on therapeutic IHC in solid tumors.Acknowledgments
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